PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
57.47 USD
-1.95 (-3.28%)
57.47 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to PBH. PBH was compared to 192 industry peers in the Pharmaceuticals industry. PBH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PBH is valued quite cheap, but it does not seem to be growing. These ratings would make PBH suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
In the past year PBH had a positive cash flow from operations.
Of the past 5 years PBH 4 years were profitable.
PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PBH has a better Return On Assets (5.83%) than 87.50% of its industry peers.
With an excellent Return On Equity value of 11.00%, PBH belongs to the best of the industry, outperforming 86.46% of the companies in the same industry.
PBH has a Return On Invested Capital of 7.88%. This is amongst the best in the industry. PBH outperforms 85.94% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PBH is below the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROIC | 7.88% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH has a Profit Margin of 18.09%. This is amongst the best in the industry. PBH outperforms 90.63% of its industry peers.
In the last couple of years the Profit Margin of PBH has grown nicely.
PBH's Operating Margin of 31.00% is amongst the best of the industry. PBH outperforms 94.27% of its industry peers.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
With a decent Gross Margin value of 56.10%, PBH is doing good in the industry, outperforming 65.63% of the companies in the same industry.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PBH is destroying value.
PBH has less shares outstanding than it did 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
PBH has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.50 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
PBH's Altman-Z score of 2.50 is fine compared to the rest of the industry. PBH outperforms 66.15% of its industry peers.
PBH has a debt to FCF ratio of 3.97. This is a good value and a sign of high solvency as PBH would need 3.97 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.97, PBH belongs to the top of the industry, outperforming 85.42% of the companies in the same industry.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
PBH has a Debt to Equity ratio of 0.55. This is in the lower half of the industry: PBH underperforms 65.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Altman-Z | 2.5 |
ROIC/WACC0.94
WACC8.38%
2.3 Liquidity
PBH has a Current Ratio of 3.70. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PBH (3.70) is comparable to the rest of the industry.
PBH has a Quick Ratio of 2.51. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PBH (2.51) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.15%, which is quite good.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
The Revenue has decreased by -0.02% in the past year.
The Revenue has been growing slightly by 3.39% on average over the past years.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 3.45% on average per year.
The Revenue is expected to grow by 1.11% on average over the next years.
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PBH is valuated correctly with a Price/Earnings ratio of 12.60.
PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 87.50% of the companies in the same industry.
PBH is valuated cheaply when we compare the Price/Earnings ratio to 25.65, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 11.92, the valuation of PBH can be described as very reasonable.
Based on the Price/Forward Earnings ratio, PBH is valued cheaper than 84.90% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.45, PBH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.6 | ||
| Fwd PE | 11.92 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaper than 88.02% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 89.58% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.07 | ||
| EV/EBITDA | 9.96 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)18.78
PEG (5Y)1.42
EPS Next 2Y3.17%
EPS Next 3Y2.82%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
57.47
-1.95 (-3.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.07%
Inst Owner Change-0.57%
Ins Owners1.29%
Ins Owner Change1.2%
Market Cap2.83B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Analysts84
Price Target79.05 (37.55%)
Short Float %3.12%
Short Ratio3.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.61%
Min EPS beat(2)-5.96%
Max EPS beat(2)9.18%
EPS beat(4)3
Avg EPS beat(4)2.04%
Min EPS beat(4)-5.96%
Max EPS beat(4)9.18%
EPS beat(8)5
Avg EPS beat(8)-0.36%
EPS beat(12)7
Avg EPS beat(12)-46.48%
EPS beat(16)11
Avg EPS beat(16)-33.78%
Revenue beat(2)1
Avg Revenue beat(2)0.1%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)5.55%
Revenue beat(4)3
Avg Revenue beat(4)0.5%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)5.55%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.15%
Revenue beat(16)9
Avg Revenue beat(16)0.5%
PT rev (1m)-7.3%
PT rev (3m)-7.3%
EPS NQ rev (1m)-9.39%
EPS NQ rev (3m)-9.15%
EPS NY rev (1m)-1.04%
EPS NY rev (3m)-0.25%
Revenue NQ rev (1m)-5.18%
Revenue NQ rev (3m)-5.27%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)-0.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.6 | ||
| Fwd PE | 11.92 | ||
| P/S | 2.55 | ||
| P/FCF | 11.07 | ||
| P/OCF | 10.74 | ||
| P/B | 1.55 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.96 |
EPS(TTM)4.56
EY7.93%
EPS(NY)4.82
Fwd EY8.39%
FCF(TTM)5.19
FCFY9.03%
OCF(TTM)5.35
OCFY9.32%
SpS22.57
BVpS37.09
TBVpS-20.21
PEG (NY)18.78
PEG (5Y)1.42
Graham Number61.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.83% | ||
| ROE | 11% | ||
| ROCE | 10.41% | ||
| ROIC | 7.88% | ||
| ROICexc | 8.17% | ||
| ROICexgc | 70.59% | ||
| OM | 31% | ||
| PM (TTM) | 18.09% | ||
| GM | 56.1% | ||
| FCFM | 23% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.97 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 27.11% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.8 | ||
| Cash Conversion | 70.49% | ||
| Profit Quality | 127.19% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 2.51 | ||
| Altman-Z | 2.5 |
F-Score7
WACC8.38%
ROIC/WACC0.94
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue 1Y (TTM)-0.02%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
EBIT growth 1Y5.81%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year7.03%
EBIT Next 3Y3.48%
EBIT Next 5Y2.99%
FCF growth 1Y18.43%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y17.36%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 7 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Undervalued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 0.67% in the next year.